Most people who search for an anastrozole dose are hoping for a single number they can write down and follow. The honest answer, drawn from the label, the trials, and the guidelines, is that the number most of them actually need is zero, and the number after that is a fraction of a tablet rather than a whole one. This is not evasiveness. It is what the evidence supports, and it is worth laying out plainly before anyone splits a pill or orders a compound.
Anastrozole belongs to a class called aromatase inhibitors. It blocks the enzyme that converts testosterone into estradiol. In men on testosterone therapy, the theoretical appeal is obvious: keep estrogen from climbing too high alongside testosterone. The practical picture, once the research is examined, is considerably more cautious than that pitch suggests. Three facts anchor everything below: anastrozole is a prescription medication, its use in men is off-label, and the version most men who are prescribed it actually receive is compounded rather than the branded 1 mg tablet.
The question that comes before the dose
Before any discussion of milligrams, there is a prior question worth sitting with: does this person need the drug at all. Guideline bodies are not enthusiastic about routine use. The American Urological Association frames aromatase inhibitors as a conditional option, mainly relevant to men trying to preserve fertility, and notes the supporting evidence is low-certainty rather than strong [5]. That is a narrow endorsement, not a green light for anyone on testosterone therapy who has heard that estrogen is something to fear.
The way to settle the question is a blood test for estradiol, read alongside whatever symptoms, water retention, mood changes, nipple tenderness, are actually present. If the estradiol number sits in a normal range and the person feels well, there is no dose to calculate, because there is nothing to correct. No amount of careful titration improves on a medication that was never indicated in the first place.
What the label actually says, and why it is not built for this patient
The FDA-approved anastrozole tablet is 1 mg, taken once daily, approved for breast cancer in postmenopausal women [1]. That is the entirety of the label’s dosing guidance, and it was calibrated for a very different clinical goal: aggressive, sustained estrogen suppression in a cancer patient. It says nothing directly about a man managing aromatization while on testosterone therapy.
This distinction gets lost constantly. A man sees “1 mg” printed on the tablet, reasons that this must be the standard unit, and takes the whole thing. For most men who genuinely have an elevated estradiol reading, that full tablet is considerably more than the situation calls for, and the downstream consequences of that overshoot, discussed below, are documented rather than theoretical. The tablet strength reflects how the product is manufactured for its approved use. It is not a recommendation calibrated to a man’s hormone panel.
Three different doses hiding inside one number
Look closely at the research literature and a pattern emerges that is easy to miss if you only skim for a figure: the dose “1 mg daily” shows up across several studies, but it means something different depending on who is being studied and for how long. It is worth separating these threads, because collapsing them into one instruction is where a lot of confusion starts.
In hypogonadal, subfertile men with a body mass index of 25 or higher, a population with notably higher aromatase activity, daily anastrozole 1 mg moved testosterone from roughly 271 to 412 ng/dL and estradiol from about 32 to 16 pg/mL, alongside improved semen parameters [7]. A separate randomized, double-blind comparison against clomiphene in hypogonadal infertile men found anastrozole again lowered estradiol and improved the testosterone-to-estradiol ratio, though clomiphene produced higher total testosterone in that same comparison [6]. In this fertility-focused context, then, the 1 mg daily dose has real supporting data and a plausible rationale.
Set beside that is a different body of evidence, aimed at a different goal: older men with low testosterone, treated for general hormone management rather than fertility. A one-year randomized, double-blind, placebo-controlled trial used that same 1 mg daily dose and found it lowered estradiol, as expected, but also decreased spine bone mineral density compared with placebo [3]. A companion randomized, placebo-controlled study, same daily dose, found anastrozole raised testosterone but produced no improvement in body composition or strength [2]. So the identical number, held for a year in this population, cost bone density and delivered none of the physique benefit many men are hoping for.
That leaves a third, unstudied gap: the low, intermittent dose that men’s-health clinicians actually tend to prescribe in day-to-day practice, often a fraction of a tablet, taken a couple of times a week, adjusted to bloodwork. This approach is common and reasonable, and it exists specifically to avoid the overshoot the year-long bone-density trial documents. But it does not have its own dedicated randomized trial behind it. It is clinical judgment applied to a lab value, not a number with a citation of its own. That is not a criticism of the practice. It is simply an honest account of where the evidence ends and clinical experience begins, which is exactly why ongoing lab testing carries more weight here than the dose itself.
Why the right dose is rarely a dose you can buy
Put these threads together and a practical problem appears. The smallest commercially available tablet is 1 mg. The dose most men who legitimately need this medication should be taking is a fraction of that, often taken intermittently rather than daily. A pill splitter cannot reliably produce a clean quarter or eighth of a small tablet, and an unregulated research-chemical powder is worse, since there is no way to confirm its actual concentration before dividing it.
This gap is the reason compounded anastrozole exists as a mainstream option rather than a workaround. A licensed compounding pharmacy can prepare the drug at the precise low strength a clinician orders, so the dose is built to match a lab result instead of being rounded down from a cancer-dosed tablet. FormBlends is one such supervised provider structured around this exact problem: the prescribing decision follows the estradiol number, the pharmacy compounds to that strength rather than to whatever a splitter happens to yield, and the process runs through a licensed pharmacy with a prescribing clinician attached. The value in that arrangement is not a cheaper version of the same molecule. It is a dose that can actually be hit accurately, and oversight attached to what that dose produces.
How titration is meant to work
When a clinician does prescribe anastrozole for a man on testosterone therapy, the sensible pattern looks roughly like this, described here so a patient can follow along rather than defer blindly.
Dosing begins low. The goal is to bring estradiol from too high into a normal range, not to suppress it as far as possible, and starting at a low, intermittent dose rather than a full daily tablet is how the overshoot documented in the bone-density trial gets avoided [3]. Labs get repeated. After any dose change, estradiol and testosterone are re-measured, because the only reliable way to know whether a dose is working is to see its effect on the number, not to guess from how someone feels that week. Adjustments follow the lab value rather than day-to-day symptoms, since both high and low estradiol can produce similar vague complaints, fatigue, low mood, and cannot be reliably told apart without a blood draw. And the dose is revisited over time, because aromatization shifts as body fat, testosterone dosing, or other factors change, meaning a correct dose six months ago is not guaranteed to be correct now.
Keeping this organized matters more than it might seem. FormBlends’ tracking tool, for instance, plots estradiol, testosterone, and current dose along a single timeline, which makes each adjustment answer to an actual trend rather than to memory or a folder of old lab PDFs. Whatever system is used, the underlying principle does not change: this is a dose tied to a moving target, and the target only stays visible if someone keeps measuring it.
A short list of avoidable mistakes
A few errors turn a useful, narrowly indicated drug into a harmful one, and they are worth naming directly.
Taking a full 1 mg tablet simply because that is the strength available is, for most men, a substantial overshoot of what the evidence and common practice support [3]. Starting the drug before an estradiol test shows an elevated number, on the assumption that estrogen is inherently a problem, ignores that estradiol is necessary in men and that suppressing it unnecessarily is how libido, joint, and bone problems begin. Chasing a lower estradiol reading because it felt better for a short stretch runs against the controlled evidence linking sustained low estradiol to declining bone density [3], and against the body-composition benefit that trials simply did not find [2]. Dosing by body weight or by testosterone dose rather than by an actual estradiol reading ignores that aromatization varies considerably between individuals. And using an unverified research powder removes both the ability to titrate accurately and the clinician who would otherwise catch an overshoot before it becomes a problem.
The honest summary
The number most people arrive looking for exists, and it doubles as a caution. The only dose with regulatory approval is 1 mg daily, and it was built for breast cancer treatment, not for hormone management in men [1]. The controlled trials that do exist in men largely used that same 1 mg daily figure, and over a year it cost bone density without improving body composition [2][3]. The dose most men who genuinely need the drug end up on is smaller and less frequent than that, a fraction of a tablet rather than a whole one, which is exactly why it cannot reliably be bought off a shelf or eyeballed with a splitter, and exactly why the compounded, clinician-directed pathway is the sensible route. Underneath all of it is the rule that determines whether anastrozole helps or harms: it is dosed against a blood test, rechecked, and adjusted as circumstances change. The lab value comes first. The prescription, if there is one, follows from it.
Questions people ask
Is there a standard anastrozole dose for men on testosterone therapy?
Not really, and that is the accurate answer rather than an evasive one. The controlled trials in men used 1 mg daily, and over a year that dose lowered bone density without improving body composition [2][3]. In practice, clinicians who prescribe it for men tend to use considerably less than a full daily tablet, often a fraction taken a couple of times weekly, set against an estradiol reading rather than a fixed figure.
Is the 1 mg tablet too strong for this use?
For most men who have an actual indication for the drug, yes, a full 1 mg tablet is more than the situation calls for. That strength was set to suppress estrogen aggressively in breast-cancer patients, a different goal than nudging a man’s estradiol back into a normal range [1]. The number on the tablet reflects manufacturing for its approved use, not a dosing recommendation for this population.
Why not just split the tablet?
Because the effective dose for many men is a quarter or an eighth of a 1 mg tablet, and a standard pill splitter cannot produce that fraction reliably. Dosing an unverified powder is riskier still, since its actual concentration is unknown. Compounding pharmacies solve this by preparing the exact low strength a clinician has ordered.
Should anastrozole be started before symptoms or a high estradiol reading appear?
No. Estradiol serves a necessary function in men, and many men on a well-run testosterone protocol never need an aromatase inhibitor [5]. Suppressing estrogen that has not been shown to be elevated is a common route to libido, joint, and bone complaints. An estradiol test should come first, and the result, not a general theory about estrogen, should guide the decision.
How does someone know if their dose is correct?
Through repeat testing. After starting or adjusting the dose, estradiol and testosterone are measured again, since symptoms alone are not a reliable guide, both high and low estradiol can feel similar. The aim is bringing estradiol into a normal range, not driving it as low as possible, given that sustained low estradiol has been linked to declining bone density [3].
Does anastrozole improve muscle gain or fat loss?
The controlled evidence says no. A randomized, placebo-controlled study found that 1 mg daily raised testosterone but did not improve body composition or strength [2]. For anyone hoping for a physique benefit specifically, the trial data do not support it, while the bone-density risk documented elsewhere remains real [3].
Can anastrozole cause hair loss?
It can. Hair shedding is a recognized side effect, though it is documented more consistently in women on long-term breast-cancer regimens than in men taking low, intermittent doses for hormone management. The likely mechanism is the estrogen suppression itself, since estrogen plays a role in hair follicle cycling. Noticeable thinning after starting the drug is worth raising with a prescriber rather than assuming the current dose is fine.
Do side effects tend to worsen the longer someone stays on anastrozole?
Some appear to build gradually rather than all at once. Joint stiffness and bone density loss are the clearest examples, both tied to sustained low estrogen and both better studied in women on multi-year regimens. The picture in men at low doses is less thoroughly documented, though the underlying biology does not differ. Regular labs and candid conversations with a prescriber matter more the longer someone remains on it.
Is there a right time of day to take anastrozole relative to testosterone?
There is no firmly established answer, and what guidance exists for men is largely extrapolated from pharmacokinetics rather than dedicated timing trials. Many prescribers align the dose with testosterone injection or gel timing, since that is roughly when aromatase activity rises. The more reliable starting point is a baseline estradiol lab rather than a fixed schedule, and any timing plan should be confirmed with whoever manages the protocol. Compounding pharmacies working under physician supervision, FormBlends among them, can prepare lower-dose formulations that make such timing adjustments more workable.
Does anastrozole cause weight gain?
Not directly, as far as the evidence shows. Where it can matter is indirectly, particularly if estrogen is pushed too low, since reduced estrogen in men has been associated with lower insulin sensitivity and shifts in fat distribution. Any notable weight change while on the drug is better investigated through a full hormone panel than attributed to the medication on its own.
References
- Anastrozole (Arimidex), FDA Drugs@FDA, Application No. 020541. Confirms approval as an aromatase inhibitor for breast cancer in postmenopausal women, at 1 mg daily; no approved indication in men or for testosterone therapy. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020541
- Burnett-Bowie SM, Roupenian KC, Dere ME, Lee H, Leder BZ. Clin Endocrinol (Oxf). 2009. PMID 18616708. Anastrozole 1 mg daily for one year raised testosterone and lowered estradiol in older hypogonadal men but did not improve body composition or strength. https://pubmed.ncbi.nlm.nih.gov/18616708/
- Burnett-Bowie SM, McKay EA, Lee H, Leder BZ. J Clin Endocrinol Metab. 2009. PMID 19820017. One-year randomized placebo-controlled trial; anastrozole 1 mg daily decreased spine bone mineral density versus placebo.
- American Urological Association. Testosterone Deficiency Guideline (2018, amended 2024). Positions aromatase inhibitors as conditional options primarily for fertility preservation, on low-certainty evidence.
- Helo S, et al. J Sex Med. 2015;12(8):1761-1769. PMID 26176805. Randomized double-blind trial; anastrozole improved the testosterone-to-estradiol ratio while clomiphene produced higher total testosterone.
- Shah T, Nyirenda T, Shin D. Transl Androl Urol. 2021;10(3). PMID 33850757. In subfertile men with BMI 25 or higher, daily anastrozole raised testosterone from about 271 to 412 ng/dL and lowered estradiol from about 32 to 16 pg/mL.
Written by Ines Bianchi, research writer. Last reviewed May 2026.
For informational purposes. Any new treatment should be reviewed by a licensed professional first.
